Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug,...

Novo Nordisk’s patent for semaglutide, the active ingredient in its weight-loss medication, expires in India this Friday. Consequently, 40 companies...

Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for...

Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for...

As Novo Nordisk’s patent on semaglutide expires, India braces for an influx of over 50 generic weight-loss drugs, promising lower prices and broader...

As Novo Nordisk’s patent on semaglutide expires, India braces for an influx of over 50 generic weight-loss drugs, promising lower prices and broader...

With the semaglutide patent ending on March 20, obesity treatment access is seen expanding globally. ......

With the semaglutide patent ending on March 20, obesity treatment access is seen expanding globally. ......

Obesity is not just about weight gain. Experts explain why improving metabolic health is key to reducing risks like diabetes, heart disease, and fatty...

Obesity is not just about weight gain. Experts explain why improving metabolic health is key to reducing risks like diabetes, heart disease, and fatty...